Weleda AG: Exceptional Partnership: Princess Madeleine and Weleda Launch New Skincare Brand, minLen

Arlesheim/Stockholm, 24 March 2025
- The first natural, responsible multi-generational skincare brand in Europe
- Princess Madeleine: “Weleda is the ideal partner for developing products that nurture and protect children's natural skin barrier. As a mother, I am mindful about the skincare products my family uses, making minLen a deeply personal project for me.”
- Weleda CEO Tina Müller: “At a time when even young children are reaching for their mother’s retinol cream, we are introducing an alternative the whole family can use without hesitation. We are honoured to have realised this important project with Madeleine.”
- First joint public appearance: 28 March 2025, Düsseldorf
Weleda AG, the global leader in certified natural skincare and anthroposophic medicines, has partnered with Princess Madeleine – under her private name, Madeleine Bernadotte – to co-develop minLen, a new natural skincare brand. This marks her entry into the beauty industry as an entrepreneur.
Through their collaboration, Madeleine Bernadotte and Weleda address a concerning social trend: children and young people are increasingly using skincare products with active ingredients unsuitable for their age. “As parents, we have a responsibility to help our children make mindful choices about skincare products,” says Madeleine Bernadotte. “I felt there was a need for a product line that not only prioritises safety but is also fun to use – made with natural ingredients, beautifully scented, and thoughtfully designed with appealing packaging for the whole family.”
The science-backed, family-friendly minLen skincare range offers exceptionally gentle, high-quality skincare, specially formulated for babies, children, and young adults. Made with natural ingredients and meeting the highest quality standards, the range has been created in close collaboration with leading experts in dermatology and natural medicine. As a mother of three, Madeleine Bernadotte understands the importance of using products specifically designed for children: “Children’s skin is delicate and requires the utmost care. That’s why Weleda is the perfect partner to create products that gently protect and strengthen their natural skin barrier.”
Tina Müller, CEO of Weleda, is thrilled about this exceptional partnership: “We are excited to have developed this new skincare line with someone as dedicated as Princess Madeleine. Her passion for this topic and her entrepreneurial spirit has inspired us from the start. The range aligns perfectly with Weleda’s primary mission: providing gentle, effective, and certified natural skincare that people around the world trust.”
Müller highlights the significance of this new joint brand as an age-appropriate alternative: “Inspired by social media, children and young people today increasingly use products that are completely unsuitable for their age, containing retinol and acids. minLen has the potential to set a new trend: 100% natural skincare that provides exceptionally gentle care and reliable protection, while redefining the fun of skincare. We combine the latest scientific insights with the power of nature to create high-quality care products for the whole family.” The minLen range harnesses the natural benefits of flax flower, wild blueberry, and sea buckthorn, known for their skin-nurturing properties.
Madeleine Bernadotte and Weleda have been working intensively on this new product family since January 2024. The brand name minLen is derived from Swedish and combines “my” (min) with “soft” (len). Len is also Princess Madeleine’s nickname.
minLen will be available from September 2025, initially in Germany, Austria, Switzerland, and Sweden – additional markets will follow. Targeted distribution will take place through Weleda web shops, perfumeries, flagship department stores, selected e-commerce platforms, and pharmacies in Sweden. The minLen product range includes face cream, shampoo & body wash, body lotion, lip balm, and body oil. Sunscreen products will be introduced for the 2026 season.
As part of the “The Art of Beauty & Health” summit, Madeleine Bernadotte and Weleda will officially launch their new brand minLen with a public presentation and a press conference on 28 March in Düsseldorf.
About Weleda
Weleda AG is a Swiss public limited company with its headquarters in Arlesheim near Basel. Weleda is represented in over 50 countries and employs around 2,500 people. Weleda is the world's leading manufacturer of certified natural cosmetics and anthroposophic pharmaceuticals. Weleda runs six gardens of its own using biodynamic cultivation methods and is particularly committed to biodiversity and healthy soils. Weleda is a certified B Corp.
More information about the Weleda Group can be found at www.weleda.com
Please note that we will address questions regarding the collaboration only during the press conference on 28 March 2025.
Media contact
Yvonne Samaritani
Group Corporate Communications Officer
Weleda AG I Dychweg 14 I CH-4144 Arlesheim
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
Dr. Stefanie Kesting appointed as CEO of Thyssengas7.1.2026 14:06:26 CET | Press release
Dortmund, 06.01.2026 As of January 1, 2026, Dr. Stefanie Kesting has been appointed as the new Chief Executive Officer (CEO) of Thyssengas GmbH. She succeeds Dr. Thomas Gößmann, who will retire at the end of February 2026 after nearly nine years at the helm of the company. The leadership transition was announced in autumn 2025.
30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength7.1.2026 08:59:31 CET | Press release
To mark its 30th anniversary, the European Spas Association (ESPA) has released a special commemorative publication highlighting the strategic role of Europe’s medical spas and climate-health resorts in an era defined by prevention, longevity and sustainable wellbeing.
Forum for a self-reliant and self-determined Europe - the "Sovereign Europe Forum"23.12.2025 08:40:47 CET | Press release
Entrepreneurs, top managers and leaders from United Europe e.V. and European Forum Alpbach (EFA) are founding the Sovereign Europe Forum i.G.
Digital Subsidiary of Austrian State Printing Company Wins Infrastructure Tender for German EU Digital Identity Wallet22.12.2025 15:12:30 CET | Press release
youniqx Identity, a digital subsidiary of the Austrian State Printing Company (OSD), has won a Europe-wide tender, together with partner companies, for the infrastructure of the German EU Digital Identity Wallet (EUDI-Wallet). EU member states are required by EU regulations to provide a national version of an EU-wide valid EUDI-Wallet by the end of 2026. Citizens will be able to use the EUDI-Wallet to prove their personal identity throughout the EU
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom